IFNG and melanoma: Inhibition of the MAPK pathway in BRAF mutant melanoma leads to increased expression of MDAs (gp100, Mart-1, Tyrp-1, and Tyrp-2), resulting in improved antigen-specific recognition by gp100 and MART-1 specific TCR-transgenic CTL as measured by increased IFN-γ production in vitro (27).